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1. Introduction 
Oxygen (O2) is often thought of as a double-edged sword: all forms of life actually need O2 
for survival as the terminal acceptor of electrons in oxidative phosphorylation, but excess O2 
might increase formation of reactive O2 species (ROS). Whereas on one hand ROS trigger 
uncontrolled burst of free radicals that lead to potentially lethal injury, on the other hand 
they act as messengers that elicit cell protection and improve survival through a variety of 
mechanisms. Although one can easily expect a link of O2 with tumor growth and metastatic 
potential, there is no univocal role for O2 in cancer. 
1.1 Hypoxia in cancer 
Lack of O2, or hypoxia, has been extensively studied in cancer because the growth of solid 
tumors requires a local vascular network that supplies O2 and nutrients to tumor cells. In the 
classical view, when cell proliferation exceeds angiogenesis, the vasculature might become 
unable to sustain the O2 needs of tumor cells, which therefore have to cope with an 
environment chronically deficient in O2 as a result of diffusion-limited O2 supply (Vaupel, 
2004). This triggers various mechanisms, most of which are mediated by over-expression of 
the hypoxia-inducible factor-1 (HIF-1). HIF-1 stimulates a variety of mechanisms aimed 
at survival of hypoxic tissue, for example the angiogenic switch, which provides growth 
factors for the development of circulation to feed the growing tumor, as well as anti-
apoptotic and cell cycle factors. Therefore, tumor hypoxia emerges as a major contributor to 
the malignant phenotype (Hockel et al., 2001) and a cause of resistance to radiation therapy 
(Brown et al., 1998).  
There are several instances whereby the O2 supply to tissues is altered. The term “hypoxia” 
is sometimes improperly attributed to any of them, but there are important differences with 
dramatically different phenotypes, as explained in Table 1. 
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Name Relative experimental situation Correlated pathologies 
Chronic hypoxia 
Prolonged O2 supply/demand 
unbalance without interruption, 
typical of decreased tissue perfusion 
for altered geometry of O2 diffusion 
from capillary to cell 
Chronic obstructive 
pulmonary disease, congenital 
heart disease, cancer-derived 
anemia, blood O2 carrying 
failure, CO poisoning, high 
altitude 
CH with 
repeated 
reoxygenation 
Animals housed in hypoxic 
chambers that are opened for 
cleaning and animal feeding 
Some cases of immature 
capillary network with 
pulsing perfusion changes 
Intermittent 
hypoxia 
Repetitive hypoxic events, typical of 
immature capillary network with 
pulsing perfusion changes 
Obstructive sleep apnea, 
sickle cell anemia crises, 
asthma, immature capillary 
network with pulsing 
perfusion changes 
Table 1. Different types of hypoxia and examples of correlated pathologies. 
1.2 Prostate cancer 
Prostate cancer is the most common neoplasia and the second most frequent cause of male 
cancer death in the developed world and in many Western countries (Hsing et al., 2000). A 
malignant tumor derived from the interaction of genetic and environmental factors, 
potentially curative treatment options are available for management of early localized 
disease, whereas palliative hormonal therapy in the form of medical or surgical castration is 
the mainstay of treatment for patients with advanced prostate cancer. Approximately 80% of 
castrated patients will suffer from a relapse of the disease within 2 years, with progression 
of the tumor from a hormone-dependent to a hormone-independent stage (Wilding, 1995), 
which is associated with unfavorable prognosis.  
In addition, prostate cancer may also represent an useful workbench to investigate the 
relationship between hypoxia and cancer, because HIF-1 is over-expressed compared with 
normal prostate epithelium (Zhong et al., 1999) and its up-regulation is recognized as an 
early event in carcinogenesis (Zhong et al., 2004). Furthermore, androgens and androgen 
receptors modulate HIF-1 levels (Kimbro et al., 2006), and hypoxia increases androgen 
receptor activity in LNCaP cells in vitro via HIF-1 (Park et al., 2006).  
1.3 Melatonin and prostate cancer 
Melatonin (N-acetyl-5-methoxytryptamine, Figure 1), a neurohormone synthesized during 
night time in the pineal gland, mediates many physiological, endocrinological and 
behavioral processes, including the well-known biorhythmic regulation of organism 
physiology, through its action on the biological clock at the hypothalamic suprachiasmatic 
nucleus (Tamarkin et al., 1985). Melatonin increases sleepiness, decreases core temperature, 
and increases peripheral temperature in humans (Brzezinski, 1997; Burgess et al., 2001; Lewy 
et al., 1996). The melatonin’s regulatory roles are mediated through high affinity G protein–
coupled receptors that reside primarily in the eye, kidney, gastrointestinal tract, blood 
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vessels, and brain (Beyer et al., 1998). This suggests some significant actions of melatonin on 
the cell biology of these target tissues outside the central nervous system as well (Cardinali 
et al., 1997; Pang et al., 1993). In addition, melatonin is known to exhibit antioxidant 
properties against the deleterious effects of reactive oxygen and nitrogen species (ROS and 
RNS, respectively) that are independent of its many receptor-mediated effects (Korkmaz et 
al., 2009; Ochoa et al., 2011). Melatonin has been reported to scavenge hydrogen peroxide 
(H2O2), hydroxyl radical (HO•), nitric oxide (NO•), peroxynitrite anion (ONOO-), 
hypochlorous acid (HOCl), singlet molecular oxygen [O2(1g)] and superoxide anion (O2•-) 
(Allegra et al., 2003; Reiter, 1998; Reiter et al., 2001; Tan et al., 2000). Melatonin has also been 
shown to possess genomic actions, through regulation of the expression of several genes 
including glutathione peroxidase, superoxide dismutase, and catalase, both under 
physiological conditions and under conditions of elevated oxidative stress (Allegra et al., 
2003; Kotler et al., 1998).  
 
 
Fig. 1. Structure of melatonin, MW 232.2 Da. 
A multitude of literature reports have documented a direct modulatory effect of melatonin 
on benign and malignant cell proliferation and an anti-tumor effect was reported both in 
vitro and in vivo in human tumors of the reproductive tissues (Cos et al., 1998; Shiu et al., 
1999). Among these, a significant role of melatonin, by itself and by interaction with sex 
steroids, has been found in the pathobiology of prostate cancer and benign prostatic 
hyperplasia (Laudon et al., 1996; Lupowitz et al., 1999). Of the various experimental prostate 
cancer models, hormone (androgen)-sensitive and hormone (androgen)-insensitive 
metastatic human prostate cancer cell lines are widely used for the experimental evaluation 
of pharmacological agents with therapeutic potential for the disease (Cho et al., 2011). In 
particular, the growth of the androgen-independent but androgen-sensitive (responsive) 
human LNCaP prostate cancer cells has been demonstrated to be inhibited by the pineal 
gland indoleamine hormone both in vitro and in vivo in a nude mice xenograft model (Siu et 
al., 2002; Xi et al., 2000). The antiproliferative action of melatonin seems to be mediated in 
part by means of MT1 receptor activation and partly by means of attenuation of 
dihydrotestosterone-induced calcium influx model (Xi et al., 2000).  
1.4 Solid lipid nanoparticles and cryopass laser therapy 
Cytostatic and antitumoral drugs activity is often impaired by low plasma solubility, poor 
systemic absorbance, rapid metabolism, non-specific tissue distribution and toxic effects. 
The search for advanced methods to deliver these molecules to target tissues and to 
overcome the failure shown even with very active drugs is therefore mandatory.  
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Solid-lipid nanoparticles (SLN) is a technology able to produce sub-micrometric lipidic 
particles characterized by an average diameter <500 nm, with a narrow size distribution 
and a spherical shape. The several advantages of this technology are listed in Table 2 
(Mehnert et al., 2001). SLN formulation of antitumor drugs is predicted to be 
advantageous with respect to other formulations because it allows greater uptake into the 
malignant cell, with consequent intracellular accumulation and higher efficacy, still 
keeping the level of free circulating drug as low as possible, thereby preventing non-
specific unwanted side effects.  
 
 
Main advantages of SLN formulation for drugs delivery. 
To control and direct the release of the drug against a specific target organ 
To modify favorably drugs pharmacokinetics  
To target directly to lymph bypassing the entero-hepatic circulation following oral 
administration  
To obtain a stealth formulation that avoids recognition by the reticuloendothelial system  
To allow oral administration of drugs poorly soluble and not easily adsorbed in the 
gastrointestinal tract 
To overcome the blood-brain barrier 
To permit administration routes as transdermal or eye topical 
Table 2. Main advantages to administer drugs as solid-lipid nanoparticles (SLN). 
Criopass therapy, is a procedure used to actively deliver drugs across the dermal barrier. It 
is based on topical application of a frozen drug emulsion in 1.5% hydroxymethylcellulose by 
means of a laser source that gives energy to penetrate the dermal barrier and deliver the 
active principle to the target area. The low energy photon flux generated by a laser beam hit 
the drug molecules frozen in the crystal lattice, exciting the electrons in the outer orbital. 
The drug molecules, when melt at the ice-skin interface, release the accumulated potential 
energy transforming into kinetic energy, which speeds up the passage of the drug across the 
skin membrane and allows to reach the target area. The last step consists in a laser scan on 
the area of drug application to optimize the adsorption through the skin and facilitate the 
drug to reach the desired site of activity. This treatment is particularly advantageous for 
treatment of bones cartilage, producing significant drug accumulation in a tissue difficult to 
be reached by traditional administration techniques. The main advantages of this non-
invasive and painless treatment are speed of absorption (15-20 s), high capacity of 
penetration (6 cm depth), suitability for polar and non-polar molecules delivery, improved 
drug bioavailability and high specificity. 
1.5 Aims 
Solid tumors contain underperfused regions where hypoxia might induce adaptation and 
cell proliferation. Often, this response is mediated by HIF-1 over-expression in hypoxic 
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cells. We demonstrated that systemic chronic in vivo hypoxia promotes prostate cancer 
growth regardless of HIF-1 expression level and neovascularization. We have also assessed 
that altering HIF-1 expression by use of non-pharmacological agents (intermittent hypoxia 
with reoxygenation) alter the phenotype of tumor growth. These observations suggest an 
important role for hypoxia dependent pathways that do not involve HIF-1, and for the 
pharmacological treatments able to modulate these pathways.  
Pharmacologic concentrations of melatonin inhibit in vitro expression of HIF-1 protein 
under both normoxic and hypoxic conditions in DU145, PC-3, and LNCaP prostate cancer 
cells (Park et al., 2009). This effect, perhaps a result of the antioxidant activity of melatonin 
against ROS induced by hypoxia, and the subsequent suppression of HIF-1 
transcriptional activity decreases VEGF expression in HCT116 human colon cancer cell 
line (Park et al., 2010). Therefore, the main aim of this preliminary study was to focus into 
the role of melatonin as a therapeutic/adjuvant agent that reduces tumor growth in vivo 
as a proof-of-concept for further studies assessing melatonin interference with the 
hypoxia signaling paths. To this purpose, we used the in-vivo model of nude mice 
xenograft with human LNCaP prostate cancer cells under a variety of conditions spanning 
from chronic hypoxia with/out reoxygenation, and compared different routes of 
melatonin administration. 
2. Methods 
Cells. LNCaP cells (80-90% confluence) were maintained in RPMI-1640 medium containing 
10% (v/v) heat-inactivated fetal bovine serum and L-glutamine, and cultured in 5% CO2. 
To ensure that LNCaP cells were not injured when passing through G26 needles during 
xenografts, we verified that their vitality did not decreased by more 2-3% per each 
passage. To obtain positive controls for HIF-1 immunostaining, LNCaP cells were 
incubated for 24 h in the presence of 100 M CoCl2, washed, fixed in formalin and stained 
as described below. 
Mice. Seven-week old Foxn1nu/nu mice (Harlan, n=46), weighing 25-30 g at the entry into the 
study, were cared in accordance to the Guide for the Care and Use of Laboratory Animals 
published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996). 
Water and bedding were heat-sterilized, whereas food was sterilized by 60Co -irradiation. 
Mice had free access to water and conventional laboratory diet until 24 h before sacrifice. A 
12/12 h light/dark cycle was maintained.  
Xenografts. LNCaP cells were resuspended in ice-cold Matrigel (1:1) at a final 
concentration of 3106/0.1 ml. Mice were inoculated in each flank with 0.1 ml of cells 
using a 26G insulin syringe. The next day, mice were transferred into the gas chamber, 
where they were treated accordingly.  
In vivo measurements of tumor growth. Body weight and tumor volume were measured three 
times a week during the various treatments. The tumor volume was calculated as 
lengthwidthheight0.5236, as measured by a caliper. Data are expressed as the ratio 
(tumor volume)/(body weight) to compensate different rates of growth in the various 
experimental situations (Figure 2). 
Sacrifice. At the end of the observation period, mice were anesthetized by i.p. Na-thiopental 
(10 mg/100 g body weight) plus heparin (500 units), then they were thoracotomized to 
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withdraw a blood sample into a heparinized syringe from the left ventricle, and tumors 
were quickly excised from surrounding skin.  
 
 
Fig. 2. Picture of a mouse at the end of the observation window. The tumors are clearly 
visible on both flanks. 
Hemoglobin. Hemoglobin (Hb) concentration was measured in blood, by diluting 10 l of 
well-stirred blood in 1 ml of Drabkin reagent, followed by incubation for 30 min at room 
temperature and absorbance reading at =540 nm. The concentration was calculated 
assuming λ=11.05 cm-1 mM-1.  
Effects of melatonin i.p.. For this set of experiments, mice xenografted with LNCaP cells as 
described above were treated with melatonin i.p. (30 µg, 1 mg/Kg), given either dissolved in 
in 100 µL isotonic saline (n=7) or encapsulated in 100 µL SLN (n=7). Mice treated with 100 
µL saline acted as control. Whereas melatonin-saline was prepared fresh, melatonin-SLN 
was obtained from Nanovector S.r.L., Torino, Italy (Gasco et al., 2007). Timing of treatments 
is given in Figure 3. 
 
 
Fig. 3. Timing of melatonin treatments. 
Effects of melatonin-laser. For this set of experiments, mice xenografted with LNCaP cells as 
described above were exposed to laser treatment with (n=11) or without (n=11) melatonin. 
Melatonin was prepared fresh every week by emulsifying 0.048 mg melatonin/mL of 1.5 % 
hydroxymethylcellulose for 7 min with a Ultraturrex at the maximum speed in ice and dark. 
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Then, 15 mL of the suspension or 0.72 mg melatonin was transferred in suitable devices and 
frozen at -20°C overnight. Each frozen stick (Figure 4A) was used to treat 6 mice.  
The final dose administered topically was about ~0.120 mg melatonin/mouse/treatment, 
i.e. 4 mg/Kg. For the administration, the stick containing frozen melatonin (or saline for the 
control group) was delivered topically for 2.4 min in the correspondence of the xenografts 
with the frozen stick connected to the laser beam. The duration of the treatment was kept 
within 2.4 min, because topical application of the frozen stick in small-size animals causes 
hypothermia (when necessary, mice were kept on a heating plate at 37°C during the 
treatment, not shown). The concentration of melatonin was selected in order to deliver the 
wanted amount in 2.4 min. After this first phase, mice were placed in a home-made device, 
immobilized and exposed for 15 min to the laser scan (the wide of the laser beam scan was 
set to the minimum value, so to cover only the small tumor area exposed on the mice back) 
(Figure 4B). We used an instrument LASERICE Med C.I.R.C.E. S.r.L., Magnago, Milano (230 
V, 50 Hz, 150 mA) constituted by a device for freezing the drug emulsion and by a scanner 
connected to photodiode laser bean with = 635 nm, maximum power <5 mW, collimation 
lens <20 mV. For our experiments, we selected the software designed for veterinary use in 
small animals. The software automatically selects the most suitable laser power and 
frequency to target the drug at the right depth into the tissues.  
 
  
A     B 
Fig. 4. (A) Topical administration of melatonin by a frozen stick connected to a low energy 
laser beam. (B) Experimental setup showing exposure of immobilized mice to high-energy 
laser scan. 
Effects of hypoxia with/out reoxygenation. Data relative to this set of experiments have been 
published in (Terraneo et al., 2010) and are here reported to enable comparing with the 
groups with melatonin. Briefly, mice xenografted with LNCaP cells as described above were 
exposed to either chronic hypoxia (10% O2) or hypoxia with reoxygenation (3 times/week 
for 1 h), with normoxia as control (n=17, 19 and 20, respectively). Hypoxia was induced by 
using the hypoxic chambers described elsewhere that prevent any unwanted contact of the 
animal with room air during cleaning operations and sacrifice (Milano et al., 2002).  
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Statistics. Data are expressed as meanSEM. Significance level was P=0.05 (two-tailed). To 
detect differences among the groups, we performed one-way ANOVA. If this test resulted 
significant, the differences between selected pairs of data were tested using the Bonferroni 
procedure (Instat 3, GraphPad software).  
3. Results 
Table 3 shows the main characteristics of the mice considered in this study. No significant 
differences were detected among the various melatonin groups as far as the changes in body 
weight and Hb concentration are concerned. By contrast, hypoxia depressed the gain in 
body weight and increased the blood Hb concentration, as expected. The marked decrease 
in body weight in the mice exposed to hypoxia forced us to shorten the 42-day observation 
window to 28 days. 
 
 n Surviving/total 
Body 
weight at 
entry, g 
Final body 
weight, g  
(42 days of 
treatment) 
Blood [Hb], g/L 
Effects of melatonin i.p. 
Saline 6/6 26.630.20 26.770.80 1203 
Melatonin-saline 7/7 27.710.32 32.170.46*# 1196 
Melatonin-SLN 7/7 27.960.25 31.940.90*# 1193 
Effects of melatonin laser 
Laser  11/11 27.240.31 29.700.91* 12611 
Laser+melatonin 11/11 27.400.30 30.580.74* 1196 
Effects of hypoxia (28 days of treatment) 
Normoxia 19/20 26.830.39 31.170.61* 1343 
Chronic hypoxia 16/17 280.46 27.380.52# 1973# 
Hypoxia with 
reoxygenation 9/9 27.550.37 23.920.28*# 2055# 
Table 3. Main characteristics of the mice considered in this study. Data from the hypoxia 
groups are published in (Terraneo et al., 2010). *, P<0.05 with respect to body weight at entry 
(unpaired two-tailed Student’s t-test); #, P<0.05 with respect to the relative control (ANOVA 
and Bonferroni post-test).  
3.1 Effect of melatonin i.p. 
This set of experiments aims at assessing whether the traditional way to administer 
melatonin results into an oncostatic situation, and whether administration of the same 
amount of melatonin is oncostatic as well. The xenograft rate of success was in the range 55-
90%. Whereas Figure 5A reports the time course of the successful xenografts, Figure 5B 
reports the time after the xenograft necessary for the xenografted tumors to be palpable. 
Data confirm that i.p. treatment with melatonin in saline has important oncostatic potential. 
Of interest, melatonin does not delay appreciably the time of appearance of the tumors after 
the xenograft, but rather it decreases the growth rate. Melatonin in SLN has less oncostatic 
potential than melatonin in saline when given in the same amount, probably as the result of 
less delivery efficiency than in the melatonin-saline group.  
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Fig. 5. Time course (A) and time necessary for the tumors to be palpable (B) in mice 
treated i.p. with either melatonin in saline or melatonin in SLN (0.51 mg 
melatonin/mouse in 17 administrations over a 42 day period), whereas saline-treated 
mice represent the control group. Data are expressed as mean SEM from 12, 10 and 8 
tumors, respectively. *, P<0.05 from untreated; #, P<0.05 from melatonin SLN (ANOVA 
and Bonferroni post-test). 
3.2 Effect of melatonin laser 
This set of experiments aims at assessing whether administering melatonin topically by 
treatment with laser results into an oncostatic situation as that described above for i.p. 
melatonin. The xenograft rate of success was in the range 75-95%. Whereas Figure 6A 
reports the time course of the successful xenografts, Figure 6B reports the time after the 
xenograft necessary for the xenografted tumors to be palpable. Whereas laser+melatonin 
results into a oncostatic situation (compare with the saline-treated as reported in Figure 4), it 
is difficult to discern an effect due to melatonin in comparison with that driven by 
laser+melatonin. 
 
    
Fig. 6. Time course (A) and time necessary for the xenografted tumors to be palpable (B) in 
mice exposed to either laser only or laser+melatonin (2.04 mg melatonin/mouse in 17 
administrations over a 42-day period). Data are expressed as meanSEM from 12, 13 and 12 
tumors, respectively. No significant difference between the two treatments was observed, 
but both laser groups are different from Saline control (*, P<0.05).  
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3.3 Effect of hypoxia 
This set of experiments aims at assessing whether inducing local hypoxia increases the 
growth of prostate tumors as published elsewhere (Terraneo et al., 2010). By decreasing 
arterial PO2 from 85 to 34 mmHg, the selected hypoxia severity (10% O2, equivalent to an 
altitude of about 5000 m) decreases the total O2 arterial content by 35%, despite the 
increased blood Hb concentration. The xenograft success rate was 56-83% without any 
significant effect of hypoxia nor its way of administration. Figure 7A reports the time course 
of the successful xenografts, and Figure 7B reports the time after the xenograft necessary for 
the tumors to be palpable. Chronic hypoxia resulted into significant increase of the tumor 
growth rate. Interestingly, an operation aimed at increasing the cytosolic abundance of HIF-
1 by approximately 10 times, e.g., exposing mice to repeated reoxygenation events during 
hypoxia, did not affected appreciably the tumor growth rate. This suggests that mechanisms 
other than those mediated by HIF-1 might have determined the increased tumor growth 
rate in hypoxic mice. 
 
    
Fig. 7. Time course (A) and time necessary for the xenografted tumors to be palpable (B) in 
mice exposed to either laser only or laser+melatonin (n g melatonin/mouse in n 
administrations over a 42 day period). Data are expressed as meanSEM from n, n and n 
tumors, respectively. *, P<0.05 from normoxia (ANOVA and Bonferroni post-test).  
4. Discussion 
Melatonin. After the first observation that in MCF-7 cells in vitro, 1 nM melatonin reduces 
tumor cells invasiveness in Falcon invasion chambers (Cos et al., 1998), the oncostatic 
properties of melatonin have been thoroughly investigated. Melatonin acts synergistically 
with castration in inhibiting growth of androgen-sensitive LNCaP tumor through opposite 
changes in cyclin D1 levels induced by activated MT1 and EGF receptors (Siu et al., 2002). As 
MT1 receptors are clearly involved in androgen-sensitive LNCaP, but not in androgen-
insensitive PC-3 cells (Xi et al., 2001), it is likely that the antiproliferative action of melatonin 
in LNCaP tumor growth is associated with MT1 receptor protein expression. Furthermore, 
the clear relationship found in MCF-7 xenografts between melatonin and telomerase 
activity, responsible of telomere elongation that activated in most human cancers (Leon-
Blanco et al., 2003), suggests that melatonin also influences telomerase decreasing its activity 
in the tumors. Although melatonin at physiologic concentration has no impact on VEGF 
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expression in three human cancer cell lines (PANC-1, HeLa and A549), at high 
pharmacological concentrations it markedly reduces expression of VEGF and HIF-1 
induced by CoCl2 in cultured cancer cells (Dai et al., 2008). A breakthrough in understanding 
the mechanisms underlying the oncostatic properties of melatonin came along with 
unraveling the relationship between melatonin and the hypoxia signaling path. Melatonin 
indeed inhibits HIF-1 protein expression in normoxic and hypoxic DU145, PC-3 and 
LNCaP prostate cancer cells without affecting HIF-1 mRNA levels (Park et al., 2009). In 
HCT116 human colon cancer cells, melatonin destabilizes HIF-1, suppresses its 
transcriptional activity, thereby decreasing VEGF expression (Park et al., 2010). In turn, these 
features block in vitro tube formation and invasion and migration of human umbilical vein 
endothelial cells induced by hypoxia media, indicating that melatonin plays a pivotal role in 
tumor suppression via inhibition of HIF-1-mediated angiogenesis. Our observation that 
melatonin inhibits LNCaP prostate cancer growth as opposite to enhanced growth in 
hypoxia agrees with the described findings. 
Chronic hypoxia. Despite the acknowledged role of hypoxia in cancer biology, mainly acquired 
through in vitro and clinical studies, accurate analysis of existing literature revealed that the 
effects of chronic hypoxia in vivo had not been investigated experimentally as well. To mimic 
chronic hypoxia, we recently developed an experimental model whereby prostate tumor-
bearing mice are exposed to various forms of hypoxia in vivo, while continuously 
monitoring tumor growth and finally assessing the molecular and cellular phenotypes 
(Terraneo et al., 2010). We found that, although hypoxia in vivo promotes prostate cancer 
growth, this could not be entirely ascribed to HIF-1, in the favor of other molecular 
pathways, such as those involving phosphatidyl inositol-3-phosphate/protein kinase B 
(Akt) pathway. This finding bears important implications especially when designing 
effective therapies: as a matter of facts, on clinical ground therapies targeting HIF-1 do not 
appear particularly successful (Fox et al., 2011). Comparing the effects led by chronic 
hypoxia with/out reoxygenation contributed to univocally assess the latter issue. 
Chronic hypoxia with reoxygenation. Reoxygenating the tumors during hypoxia increased HIF-1 
cytosolic level >10-fold more than in chronic hypoxia, yet tumor growth was essentially 
similar to that of chronic hypoxia (Terraneo et al., 2010). Higher HIF-1 in reoxygenated 
tumors with respect to chronic hypoxia could be a consequence of shorter normalization time 
since the last exposure to hypoxia (2-3 days), or of reoxygenation-induced HIF-1 stabilization 
or enhanced synthesis. As the reoxygenation of hypoxic tissues causes considerable oxidative 
stress (Milano et al., 2004), the associated enhanced generation of mitochondrial ROS may 
stabilize HIF-1 (Chandel et al., 2000). It has also been proposed that the persistent oxidative 
stress promoted by ROS during the reoxygenation further amplifies HIF-1 activation in a 
feed-forward mechanism through a mechanism involving mTOR (Semenza et al., 2007). 
Therefore, although this finding was key to suppose non-centrality of HIF-1 in cancer 
growth, the effect of HIF-1 on metastatic potential is still to be investigated.  
Therapeutic potential and future perspectives. The role of melatonin as anti-proliferative factor 
in the management of prostate cancer is currently under study by several research groups. 
However, its signaling mechanism and its crosstalk with other positive or negative growth 
regulator factors as HIF-1, sex steroids, epidermal growth factor (EGF), vascular 
endothelial growth factor (VEGF) and others is still under debate and deserves to be 
thoroughly investigated. Moreover, to elucidate the biological effects of melatonin under 
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physiological and pathological conditions, its putative antioxidant action is to be studied. 
Finally, the effect of melatonin on sarcosine (N-methyl derivative of the amino acid glycine), 
a potentially important metabolic intermediary of cancer cell invasion and aggressivity 
(Sreekumar et al., 2009) merits future attention. 
5. Conclusion 
In vivo systemic hypoxia promotes prostate cancer growth regardless of HIF-1 expression 
level and neovascularization, suggesting an important role for hypoxia-dependent 
pathways that do not involve HIF-1, as the phosphatidyl inositol-3-phosphate signaling 
cascade. Melatonin experiments may not only provide a useful probe to assess the effects of 
HIF-1 on tumor growth, but may also represent the basis for the future introduction of this 
natural molecule as adjuvant active component in novel therapeutic strategies for the 
treatment of malignant prostate cancer in humans, for the prevention of cancer relapses, or 
simply for the amelioration of the quality of life of the oncologic patient.  
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